Patent intelligence · US
US 11814439
Anti-CD20 antibody compositions
Anti-CD20 antibody compositions
Patent details — US 11814439
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 14, 2023
- Expiration
- Nov 9, 2043
- Applicant
- TG Therapeutics, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K2039/545, A61K31/138, A61K31/167
Quick answer
US 11814439 (Anti-CD20 antibody compositions) is held by TG Therapeutics, Inc.. Status: granted. Granted Nov 14, 2023. Expires Nov 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TG Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2039/545, A61K31/138, A61K31/167, A61K31/573, A61P
More from TG Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11965032
Anti-CD20 antibody compositions
granted -
US 11884740
Anti-CD20 antibody compositions
granted -
US 11807689
Anti-CD20 antibody compositions
granted -
US 10966977
Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
granted -
US 10729768
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
granted -
US 9694071
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
granted
Frequently asked questions
What is US patent 11814439?
US 11814439 (Anti-CD20 antibody compositions) is held by TG Therapeutics, Inc.. Status: granted. Granted Nov 14, 2023. Expires Nov 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11814439?
TG Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11814439 expire?
Our index shows an expiration date of Nov 9, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.